Traditional Chinese acupuncture versus minimal acupuncture for mild-to-moderate knee osteoarthritis: a protocol for a randomised, controlled pilot trial by Guang-Xia Shi, Cun-Zhi Liu, Ning Sun, Yi Du, Jian-Feng Tu, Yong-Ting Li, Li-Wen Zhang, Yan Cao, Jing-Jie Zhao, Da-Chang Xiong, Hai-Kun Hou

“…Secondary end points include pain and function measurement, global change, the quality of life and the use of non-steroidal anti-inflammatory drugs (Celebrex, Pfizer) at 8, 16 and 26 weeks.Ethics and dissemination Ethical approval of this study has been granted by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (permission number: 2016BL-010-02). …”
Get full text

Papel del Estado en la campaña de vacunación contra la COVID-19 a través del ordenamiento jurídico by Rodolfo Arevalo Marcos, Yolanda Maria Siguas Astorga, Marcos Antonio Montoro Valdivia, José Luis Salazar Huarote

“…Durante el proceso de emergencia, las vacunas que aprobaron las autoridades para la población fueron las Pfizer-BioNTech, Moderna, Sputnik, Jhonson & Jhonson, AstraZeneca, Sinopharm, Sinovac, Covaxin y Covocax. …”
Get full text

The incidence of radiologically verified community-acquired pneumonia requiring hospitalisation in adults living in southern Sweden, 2016-2018: a population-based study by Elisabeth Rünow, Frida Valeur, Gustav Torisson, Karin Hansen, Christian Theilacker, Kristian Riesbeck, Jonas Ahl

Get full text

Ten proposed measures to improve vaccination: Health care providers’ perspectives on promoting the vaccination intake of children with special healthcare needs in China by Xiang Guo, Tianxing Feng, Meiyi Chen, Xuran Zhao, Xiangshi Wang, Yanling Ge, Zhonglin Wang, Zhuoying Huang, Mei Zeng

Get full text

The effect of meningococcal vaccines on new generation of systemic inflammatory markers in children by Omer Okuyan, Neval Elgormus, Seyma Dumur, Ugurcan Sayili, Hafize Uzun

“…The data of those who received the first 2 doses at 2-month intervals and the next dose between 8–12 months were included. Nimenrix® (Pfizer) administered as a single dose to children from 12 months of age. …”
Get full text

Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus by Marco Daperno, Alessandro Armuzzi, Silvio Danese, Walter Fries, Giuseppina Liguori, Ambrogio Orlando, Claudio Papi, Mariabeatrice Principi, Fernando Rizzello, Angelo Viscido, Paolo Gionchetti

Get full text

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus by Min Lin, Yifan Yin, Xiaomeng Zhao, Chen Wang, Xueqing Zhu, Letao Zhan, Li Chen, Siling Wang, Xue Lin, Jun Zhang, Ningshao Xia, Zizheng Zheng

“…Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, Pfizer and Moderna to protect high-risk populations against respiratory syncytial virus (RSV). …”
Get full text

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals by Sophie Tourdot, Daniel Baltrunkonis, Sofie Denies, Viswanath Devanarayan, Joanna Grudzinska-Goebel, Arno Kromminga, Gregor P. Lotz, Laurent Malherbe, Lydia Michaut, Karin N. Weldingh, Joao A. Pedras-Vasconcelos, Laura. I. Salazar-Fontana, Sebastian Spindeldreher, Zuben Sauna, Veerle Snoeck, Daniela Verthelyi, Daniel Kramer

Get full text

Estudio de reactogenicidad en las vacunas mRNA frente a la COVID-19 by Joan Inglés Torruella, Rosa Maria Gil Soto, Esther Sabaté Aguila, Mercé García Grau, Nina Pons Boronat, Adelaida Rubio Civit, Miriam Bandera Baez, Gustavo Moreno Martin

“… Objetivo: Comparar la reactogenicidad entre los tipos de vacuna RNAm Commirnaty® (Pfizer) y Spikevax® (Moderna) frente a la COVID-19 en población sanitaria. …”
Get full text

Healthcare resource utilisation and costs of hospitalisation and primary care among adults with COVID-19 in England: a population-based cohort study by Carmen Tsang, Robert Wood, Tendai Mugwagwa, Kiran K Rai, Jingyan Yang, Theo Tritton, Jennifer L Nguyen, Kathleen Michelle Andersen, Maya Reimbaeva, Leah J McGrath, Poppy Payne, Bethany Emma Backhouse, Diana Mendes, Rebecca Butfield, Kevin Naicker, Mary Araghi

Get full text

Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain) by Ana C. Montagud, Raul Moragues, Nancy Vicente-Alcalde, Nancy Vicente-Alcalde, Emilia Montagud, José Antonio Hurtado-Sánchez, José Antonio Hurtado-Sánchez, José Tuells, José Tuells

“…The vaccines administered in the last dose were Biontech/Pfizer and Moderna in 88.6% of the cases. 59.5% of sample had suffered from COVID-19 and 67.0% did not have any clinical comorbidity. …”
Get full text

Humoral and cellular immune durability of different COVID-19 vaccine platforms following homologous/heterologous boosters: one-year post vaccination by Maaweya Awadalla, Halah Z. AlRawi, Rahaf A. Henawi, Fawziya Barnawi, Haitham Alkadi, Ahmed Alyami, Ammar Alsughayir, Alyazeed S. Alsaif, Ayman Mubarak, Wael Alturaiki, Bandar Alosaimi

“…IntroductionThe durability of Hybrid immunity induced by natural infection and/or COVID-19 vaccines and evidence supporting further booster vaccination are crucial factors for pandemic response, yet remain poorly understood.MethodsWe measured the durability of immune response and neutralizing capacity of antibodies following Homologous/Heterologous vaccination by mRNA-based vaccines (Pfizer-BioNTech BNT162b2) or (Moderna mRNA-1273) and viral vector-based vaccines (ChAdox1 nCoV-19-Oxford-AstraZeneca) in infected and non-infected patients. …”
Get full text

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease by Ayaka Hayashi, Ayaka Hayashi, Hiroto Ishihara, Mayuko Kawabe, Kazuhiko Kato, Kazuhiko Kato, Akio Nakashima, Akio Nakashima, Izumi Yamamoto, Teppei Sakano, Teppei Sakano, Hiroe Kobashi, Makoto Morita, Makoto Morita, Takashi Yokoo, Mitsuyoshi Urashima

Get full text

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a m... by Ernest Choy, Kerenza Hood, Emma Thomas-Jones, Eleanor Barnes, Keith Wilson, Christian H Ottensmeier, Debbie Harris, Adrian Hill, Mark Tuthill, Richard Adams, Catherine Porter, Katie Ewer, Sian Griffin, Rebecca Tangney, Joanne Euden, Shirley Pringle, Lawrence Raisanen, Ruby Ray, Lisette Sheena Nixon, Melanie Varley, Craig Bodman, Paola Cicconi, Vivien Dagley, Steven Knapper

“…Participants will be randomised (1:1) to the Moderna vaccine or Pfizer/BioNTech vaccine. Participant samples will be taken at baseline and at multiple timepoints after the administration of AZD7442.Analysis The participant samples will be analysed to measure the function and magnitude of SARS-CoV-2 specific antibody and T-cell responses at baseline and at multiple timepoints after the administration of AZD7442. …”
Get full text

Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants by Odile Launay, Rachna Gupta, Tifany Machabert, Eleine Konate, Alexandra Rousseau, Claire Vigne, Francois Beckers, Louis Devlin, Elisabeth Botelho-Nevers, Marine Cachanado, Christian Chidiac, Dominique Deplanque, Bertrand Dussol, Inès Ben Ghezala, Marie Lachatre, Karine Lacombe, Fabrice Laine, Liem Binh Luong Nguyen, Patricia Pavese, Catherine Schmidt-Mutter, Marie-Pierre Tavolacci, Roman M. Chicz, Bogdana Coudsy, Saranya Sridhar, Amel Touati, Eric Tartour, Tabassome Simon

“…Abstract Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. …”
Get full text

Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination by Nicole L Messina, Susie Germano, Amy W Chung, Carolien E van deSandt, Natalie E Stevens, Lilith F Allen, Rhian Bonnici, Julio Croda, Claudio Counoupas, Branka Grubor‐Bauk, Ebene R Haycroft, Katherine Kedzierska, Ellie McDonald, Rebecca McElroy, Mihai G Netea, Boris Novakovic, Kirsten P Perrett, Laure F Pittet, Ruth A Purcell, Kanta Subbarao, James A Triccas, David J Lynn, Nigel Curtis, the BRACE Trial Consortium Group

“…Methods Blood samples, from a subset of 275 SARS‐CoV‐2‐naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1‐S (Oxford‐AstraZeneca) or BNT162b2 (Pfizer‐BioNTech) vaccination. SARS‐CoV‐2‐specific antibodies were measured using ELISA and multiplex bead array, whole blood cytokine responses to γ‐irradiated SARS‐CoV‐2 (iSARS) stimulation were measured by multiplex bead array, and SARS‐CoV‐2‐specific T‐cell responses were measured by activation‐induced marker and intracellular cytokine staining assays. …”
Get full text